ID   PANK2_HUMAN             Reviewed;         570 AA.
AC   Q9BZ23; B1AK33; B2Z3X0; D3DVZ0; Q5T7I2; Q5T7I4; Q7RTX5; Q8N7Q4;
AC   Q8TCR5; Q9BYW5; Q9HAF2;
DT   17-JAN-2003, integrated into UniProtKB/Swiss-Prot.
DT   28-NOV-2006, sequence version 3.
DT   10-MAY-2017, entry version 153.
DE   RecName: Full=Pantothenate kinase 2, mitochondrial;
DE            Short=hPanK2;
DE            EC=2.7.1.33;
DE   AltName: Full=Pantothenic acid kinase 2;
DE   Flags: Precursor;
GN   Name=PANK2; Synonyms=C20orf48;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ALA-126, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Brain;
RX   PubMed=12554685; DOI=10.1093/hmg/ddg026;
RA   Hoertnagel K., Prokisch H., Meitinger T.;
RT   "An isoform of hPANK2, deficient in pantothenate kinase-associated
RT   neurodegeneration, localizes to mitochondria.";
RL   Hum. Mol. Genet. 12:321-327(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 106-570 (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-94; GLN-111 AND
RP   ALA-126.
RG   NIEHS SNPs program;
RL   Submitted (MAR-2008) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 406-570.
RC   TISSUE=Brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   IDENTIFICATION, ALTERNATIVE INITIATION AT LEU-111, VARIANTS GLN-111
RP   AND ALA-126, VARIANTS NBIA1 VAL-219; ALA-234; TRP-264; CYS-278;
RP   VAL-282; CYS-286; ILE-327; PRO-351; SER-355; ILE-404; PRO-413;
RP   ASN-471; THR-497; ILE-500; ARG-521 AND MET-528, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=11479594; DOI=10.1038/ng572;
RA   Zhou B., Westaway S.K., Levinson B., Johnson M.A., Gitschier J.,
RA   Hayflick S.J.;
RT   "A novel pantothenate kinase gene (PANK2) is defective in
RT   Hallervorden-Spatz syndrome.";
RL   Nat. Genet. 28:345-349(2001).
RN   [8]
RP   INVOLVEMENT IN HARP.
RX   PubMed=12058097; DOI=10.1212/WNL.58.11.1673;
RA   Ching K.H.L., Westaway S.K., Gitschier J., Higgins J.J.,
RA   Hayflick S.J.;
RT   "HARP syndrome is allelic with pantothenate kinase-associated
RT   neurodegeneration.";
RL   Neurology 58:1673-1674(2002).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-168; SER-169 AND
RP   SER-189, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-168; SER-169 AND
RP   SER-189, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-189, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-168 AND SER-189, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-168 AND SER-189, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-168 AND SER-189, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   VARIANTS NBIA1 GLY-134; PRO-249; LEU-278; ASP-322; GLY-322; GLN-357;
RP   THR-398; LEU-425 DEL; TYR-428; ASN-447; THR-501; VAL-509; ASP-511;
RP   TRP-532; PRO-563 AND LEU-570.
RX   PubMed=12510040; DOI=10.1056/NEJMoa020817;
RA   Hayflick S.J., Westaway S.K., Levinson B., Zhou B., Johnson M.A.,
RA   Ching K.H., Gitschier J.;
RT   "Genetic, clinical, and radiographic delineation of Hallervorden-Spatz
RT   syndrome.";
RL   N. Engl. J. Med. 348:33-40(2003).
RN   [17]
RP   VARIANTS NBIA1 ARG-521 AND LEU-570.
RX   PubMed=15834858; DOI=10.1002/mds.20476;
RA   Nicholas A.P., Earnst K.S., Marson D.C.;
RT   "Atypical Hallervorden-Spatz disease with preserved cognition and
RT   obtrusive obsessions and compulsions.";
RL   Mov. Disord. 20:880-886(2005).
RN   [18]
RP   VARIANTS NBIA1 ARG-521 AND SER-555.
RX   PubMed=24075960; DOI=10.1016/j.ejmg.2013.08.007;
RA   Perez-Gonzalez E.A., Chacon-Camacho O.F., Arteaga-Vazquez J.,
RA   Zenteno J.C., Mutchinick O.M.;
RT   "A novel gene mutation in PANK2 in a patient with an atypical form of
RT   pantothenate kinase-associated neurodegeneration.";
RL   Eur. J. Med. Genet. 56:606-608(2013).
RN   [19]
RP   VARIANT NBIA1 SER-377.
RX   PubMed=22930366; DOI=10.1007/s10072-012-1177-8;
RA   Shan J., Wen B., Zhu J., Lin P., Zheng J., Yan C.;
RT   "Novel PANK2 gene mutations in two Chinese siblings with atypical
RT   pantothenate kinase-associated neurodegeneration.";
RL   Neurol. Sci. 34:561-563(2013).
RN   [20]
RP   VARIANT NBIA1 GLY-232.
RX   PubMed=24655737; DOI=10.1016/j.jns.2014.03.001;
RA   Tanteles G.A., Spanou-Aristidou E., Antoniou C.,
RA   Christophidou-Anastasiadou V., Kleopa K.A.;
RT   "Novel homozygous PANK2 mutation causing atypical pantothenate kinase-
RT   associated neurodegeneration (PKAN) in a Cypriot family.";
RL   J. Neurol. Sci. 340:233-236(2014).
RN   [21]
RP   VARIANTS NBIA1 PRO-489 AND MET-528.
RX   PubMed=27185474; DOI=10.1016/j.braindev.2016.02.010;
RA   Yapici Z., Akcakaya N.H., Tekturk P., Iseri S.A., Ozbek U.;
RT   "A novel gene mutation in PANK2 in a patient with severe jaw-opening
RT   dystonia.";
RL   Brain Dev. 38:755-758(2016).
CC   -!- FUNCTION: May be the master regulator of the CoA biosynthesis.
CC       {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: ATP + (R)-pantothenate = ADP + (R)-4'-
CC       phosphopantothenate.
CC   -!- ENZYME REGULATION: Regulated by feedback inhibition by CoA and its
CC       thioesters.
CC   -!- PATHWAY: Cofactor biosynthesis; coenzyme A biosynthesis; CoA from
CC       (R)-pantothenate: step 1/5.
CC   -!- SUBUNIT: Homodimer. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Mitochondrion.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Cytoplasm {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Cytoplasm {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q9BZ23-1; Sequence=Displayed;
CC       Name=3;
CC         IsoId=Q9BZ23-2; Sequence=VSP_007424;
CC       Name=2;
CC         IsoId=Q9BZ23-3; Sequence=VSP_018825;
CC         Note=Produced by alternative initiation at Met-124 of isoform
CC         1.;
CC       Name=4;
CC         IsoId=Q9BZ23-4; Sequence=VSP_038494, VSP_038495;
CC         Note=May be produced by alternative initiation at Leu-111 of
CC         isoform 1. No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:11479594}.
CC   -!- DISEASE: Neurodegeneration with brain iron accumulation 1 (NBIA1)
CC       [MIM:234200]: Autosomal recessive neurodegenerative disorder
CC       associated with iron accumulation in the brain, primarily in the
CC       basal ganglia. Clinical manifestations include progressive muscle
CC       spasticity, hyperreflexia, muscle rigidity, dystonia, dysarthria,
CC       and intellectual deterioration which progresses to severe dementia
CC       over several years. It is clinically classified into classic,
CC       atypical, and intermediate phenotypes. Classic forms present with
CC       onset in first decade, rapid progression, loss of independent
CC       ambulation within 15 years. Atypical forms have onset in second
CC       decade, slow progression, maintenance of independent ambulation up
CC       to 40 years later. Intermediate forms manifest onset in first
CC       decade with slow progression or onset in second decade with rapid
CC       progression. Patients with early onset tend to also develop
CC       pigmentary retinopathy, whereas those with later onset tend to
CC       also have speech disorders and psychiatric features. All patients
CC       have the 'eye of the tiger' sign on brain MRI.
CC       {ECO:0000269|PubMed:11479594, ECO:0000269|PubMed:12510040,
CC       ECO:0000269|PubMed:15834858, ECO:0000269|PubMed:22930366,
CC       ECO:0000269|PubMed:24075960, ECO:0000269|PubMed:24655737,
CC       ECO:0000269|PubMed:27185474}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Hypoprebetalipoproteinemia, acanthocytosis, retinitis
CC       pigmentosa, and pallidal degeneration (HARP) [MIM:607236]: Rare
CC       syndrome with many clinical similarities to PKAN.
CC       {ECO:0000269|PubMed:12058097}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: The HSS syndrome has been proposed to be renamed
CC       because of the unethical activities of Julius Hallervorden and
CC       Hugo Spatz during world war II.
CC   -!- SIMILARITY: Belongs to the type II pantothenate kinase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC05173.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/pank2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF494409; AAN32907.1; -; mRNA.
DR   EMBL; AK021791; BAB13897.1; -; mRNA.
DR   EMBL; AK097796; BAC05173.1; ALT_INIT; mRNA.
DR   EMBL; EU595875; ACD11492.1; -; Genomic_DNA.
DR   EMBL; AL353194; CAI11036.1; -; Genomic_DNA.
DR   EMBL; AL031670; CAI11036.1; JOINED; Genomic_DNA.
DR   EMBL; AL353194; CAI11037.1; -; Genomic_DNA.
DR   EMBL; AL031670; CAI11037.1; JOINED; Genomic_DNA.
DR   EMBL; AL031670; CAI22385.1; -; Genomic_DNA.
DR   EMBL; AL353194; CAI22385.1; JOINED; Genomic_DNA.
DR   EMBL; AL031670; CAI22386.1; -; Genomic_DNA.
DR   EMBL; AL353194; CAI22386.1; JOINED; Genomic_DNA.
DR   EMBL; CH471133; EAX10478.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10476.1; -; Genomic_DNA.
DR   EMBL; AL713654; CAD28463.1; -; mRNA.
DR   EMBL; BK000010; DAA00004.1; -; mRNA.
DR   CCDS; CCDS13071.2; -. [Q9BZ23-1]
DR   CCDS; CCDS13072.1; -. [Q9BZ23-2]
DR   RefSeq; NP_001311120.1; NM_001324191.1. [Q9BZ23-2]
DR   RefSeq; NP_079236.3; NM_024960.5. [Q9BZ23-2]
DR   RefSeq; NP_705902.2; NM_153638.3. [Q9BZ23-1]
DR   RefSeq; NP_705904.1; NM_153640.3. [Q9BZ23-2]
DR   RefSeq; XP_005260893.3; XM_005260836.4. [Q9BZ23-2]
DR   UniGene; Hs.114180; -.
DR   UniGene; Hs.516859; -.
DR   PDB; 5E26; X-ray; 2.14 A; A/B/C/D=205-568.
DR   PDBsum; 5E26; -.
DR   ProteinModelPortal; Q9BZ23; -.
DR   SMR; Q9BZ23; -.
DR   BioGrid; 123079; 12.
DR   IntAct; Q9BZ23; 3.
DR   MINT; MINT-3319143; -.
DR   STRING; 9606.ENSP00000313377; -.
DR   BindingDB; Q9BZ23; -.
DR   ChEMBL; CHEMBL3407327; -.
DR   iPTMnet; Q9BZ23; -.
DR   PhosphoSitePlus; Q9BZ23; -.
DR   BioMuta; PANK2; -.
DR   DMDM; 118572682; -.
DR   EPD; Q9BZ23; -.
DR   MaxQB; Q9BZ23; -.
DR   PaxDb; Q9BZ23; -.
DR   PeptideAtlas; Q9BZ23; -.
DR   PRIDE; Q9BZ23; -.
DR   TopDownProteomics; Q9BZ23-1; -. [Q9BZ23-1]
DR   Ensembl; ENST00000316562; ENSP00000313377; ENSG00000125779. [Q9BZ23-1]
DR   Ensembl; ENST00000497424; ENSP00000417609; ENSG00000125779. [Q9BZ23-2]
DR   Ensembl; ENST00000610179; ENSP00000477429; ENSG00000125779. [Q9BZ23-3]
DR   Ensembl; ENST00000621507; ENSP00000481523; ENSG00000125779. [Q9BZ23-2]
DR   GeneID; 80025; -.
DR   KEGG; hsa:80025; -.
DR   UCSC; uc002wkb.4; human. [Q9BZ23-1]
DR   CTD; 80025; -.
DR   DisGeNET; 80025; -.
DR   GeneCards; PANK2; -.
DR   GeneReviews; PANK2; -.
DR   HGNC; HGNC:15894; PANK2.
DR   HPA; HPA008440; -.
DR   MalaCards; PANK2; -.
DR   MIM; 234200; phenotype.
DR   MIM; 606157; gene.
DR   MIM; 607236; phenotype.
DR   neXtProt; NX_Q9BZ23; -.
DR   OpenTargets; ENSG00000125779; -.
DR   Orphanet; 216873; Atypical pantothenate kinase-associated neurodegeneration.
DR   Orphanet; 216866; Classic pantothenate kinase-associated neurodegeneration.
DR   PharmGKB; PA38048; -.
DR   eggNOG; KOG2201; Eukaryota.
DR   eggNOG; COG5146; LUCA.
DR   GeneTree; ENSGT00390000020719; -.
DR   HOVERGEN; HBG053495; -.
DR   InParanoid; Q9BZ23; -.
DR   KO; K09680; -.
DR   OMA; KRQFNFS; -.
DR   OrthoDB; EOG091G0851; -.
DR   PhylomeDB; Q9BZ23; -.
DR   TreeFam; TF314866; -.
DR   BioCyc; MetaCyc:HS13177-MONOMER; -.
DR   BRENDA; 2.7.1.33; 2681.
DR   Reactome; R-HSA-196783; Coenzyme A biosynthesis.
DR   SABIO-RK; Q9BZ23; -.
DR   UniPathway; UPA00241; UER00352.
DR   ChiTaRS; PANK2; human.
DR   GeneWiki; PANK2_(gene); -.
DR   GenomeRNAi; 80025; -.
DR   PRO; PR:Q9BZ23; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000125779; -.
DR   CleanEx; HS_PANK2; -.
DR   ExpressionAtlas; Q9BZ23; baseline and differential.
DR   Genevisible; Q9BZ23; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005758; C:mitochondrial intermembrane space; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004594; F:pantothenate kinase activity; TAS:Reactome.
DR   GO; GO:0009060; P:aerobic respiration; IEA:Ensembl.
DR   GO; GO:0015937; P:coenzyme A biosynthetic process; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0009108; P:coenzyme biosynthetic process; TAS:Reactome.
DR   GO; GO:0070584; P:mitochondrion morphogenesis; IEA:Ensembl.
DR   GO; GO:0015939; P:pantothenate metabolic process; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0016310; P:phosphorylation; NAS:ParkinsonsUK-UCL.
DR   GO; GO:1904251; P:regulation of bile acid metabolic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0019217; P:regulation of fatty acid metabolic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0051881; P:regulation of mitochondrial membrane potential; IEA:Ensembl.
DR   GO; GO:0090207; P:regulation of triglyceride metabolic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0007286; P:spermatid development; IEA:Ensembl.
DR   InterPro; IPR004567; Type_II_PanK.
DR   Pfam; PF03630; Fumble; 1.
DR   TIGRFAMs; TIGR00555; panK_eukar; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Alternative splicing;
KW   ATP-binding; Coenzyme A biosynthesis; Complete proteome; Cytoplasm;
KW   Disease mutation; Kinase; Mitochondrion; Neurodegeneration;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Transferase; Transit peptide.
FT   TRANSIT       1     46       Mitochondrion. {ECO:0000255}.
FT   CHAIN        47    570       Pantothenate kinase 2, mitochondrial.
FT                                /FTId=PRO_0000023201.
FT   COMPBIAS    236    243       Poly-Glu.
FT   BINDING     392    392       Acetyl-CoA. {ECO:0000250}.
FT   BINDING     395    395       Acetyl-CoA. {ECO:0000250}.
FT   BINDING     407    407       Acetyl-CoA. {ECO:0000250}.
FT   MOD_RES     168    168       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     169    169       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332}.
FT   MOD_RES     189    189       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ       1    291       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_007424.
FT   VAR_SEQ       1    123       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_018825.
FT   VAR_SEQ       1    110       Missing (in isoform 4). {ECO:0000305}.
FT                                /FTId=VSP_038494.
FT   VAR_SEQ     111    111       L -> M (in isoform 4). {ECO:0000305}.
FT                                /FTId=VSP_038495.
FT   VARIANT      94     94       R -> P (in dbSNP:rs71647827).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_054484.
FT   VARIANT     111    111       L -> Q (in dbSNP:rs71647828).
FT                                {ECO:0000269|PubMed:11479594,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_015152.
FT   VARIANT     126    126       G -> A (in dbSNP:rs3737084).
FT                                {ECO:0000269|PubMed:11479594,
FT                                ECO:0000269|PubMed:12554685,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_015153.
FT   VARIANT     134    134       E -> G (in NBIA1; dbSNP:rs765679726).
FT                                {ECO:0000269|PubMed:12510040}.
FT                                /FTId=VAR_060934.
FT   VARIANT     219    219       G -> V (in NBIA1; atypical).
FT                                {ECO:0000269|PubMed:11479594}.
FT                                /FTId=VAR_015154.
FT   VARIANT     232    232       D -> G (in NBIA1; atypical; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:24655737}.
FT                                /FTId=VAR_076594.
FT   VARIANT     234    234       T -> A (in NBIA1; atypical;
FT                                dbSNP:rs137852965).
FT                                {ECO:0000269|PubMed:11479594}.
FT                                /FTId=VAR_015155.
FT   VARIANT     249    249       R -> P (in NBIA1).
FT                                {ECO:0000269|PubMed:12510040}.
FT                                /FTId=VAR_060935.
FT   VARIANT     264    264       R -> W (in NBIA1; dbSNP:rs137852961).
FT                                {ECO:0000269|PubMed:11479594}.
FT                                /FTId=VAR_015156.
FT   VARIANT     278    278       R -> C (in NBIA1; atypical;
FT                                dbSNP:rs137852966).
FT                                {ECO:0000269|PubMed:11479594}.
FT                                /FTId=VAR_015157.
FT   VARIANT     278    278       R -> L (in NBIA1).
FT                                {ECO:0000269|PubMed:12510040}.
FT                                /FTId=VAR_060936.
FT   VARIANT     282    282       L -> V (in NBIA1).
FT                                {ECO:0000269|PubMed:11479594}.
FT                                /FTId=VAR_015158.
FT   VARIANT     286    286       R -> C (in NBIA1; dbSNP:rs137852962).
FT                                {ECO:0000269|PubMed:11479594}.
FT                                /FTId=VAR_015159.
FT   VARIANT     322    322       E -> D (in NBIA1; atypical).
FT                                {ECO:0000269|PubMed:12510040}.
FT                                /FTId=VAR_060937.
FT   VARIANT     322    322       E -> G (in NBIA1; dbSNP:rs768230831).
FT                                {ECO:0000269|PubMed:12510040}.
FT                                /FTId=VAR_060938.
FT   VARIANT     327    327       T -> I (in NBIA1).
FT                                {ECO:0000269|PubMed:11479594}.
FT                                /FTId=VAR_015160.
FT   VARIANT     351    351       S -> P (in NBIA1; atypical;
FT                                dbSNP:rs137852964).
FT                                {ECO:0000269|PubMed:11479594}.
FT                                /FTId=VAR_015161.
FT   VARIANT     355    355       N -> S (in NBIA1; atypical;
FT                                dbSNP:rs746484727).
FT                                {ECO:0000269|PubMed:11479594}.
FT                                /FTId=VAR_015162.
FT   VARIANT     357    357       R -> Q (in NBIA1; dbSNP:rs754521581).
FT                                {ECO:0000269|PubMed:12510040}.
FT                                /FTId=VAR_060939.
FT   VARIANT     377    377       F -> S (in NBIA1; atypical; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:22930366}.
FT                                /FTId=VAR_076595.
FT   VARIANT     398    398       A -> T (in NBIA1; dbSNP:rs759223327).
FT                                {ECO:0000269|PubMed:12510040}.
FT                                /FTId=VAR_060940.
FT   VARIANT     404    404       N -> I (in NBIA1; atypical;
FT                                dbSNP:rs752078407).
FT                                {ECO:0000269|PubMed:11479594}.
FT                                /FTId=VAR_015163.
FT   VARIANT     413    413       L -> P (in NBIA1; dbSNP:rs750176786).
FT                                {ECO:0000269|PubMed:11479594}.
FT                                /FTId=VAR_015164.
FT   VARIANT     425    425       Missing (in NBIA1).
FT                                {ECO:0000269|PubMed:12510040}.
FT                                /FTId=VAR_060941.
FT   VARIANT     428    428       C -> Y (in NBIA1).
FT                                {ECO:0000269|PubMed:12510040}.
FT                                /FTId=VAR_060942.
FT   VARIANT     447    447       D -> N (in NBIA1).
FT                                {ECO:0000269|PubMed:12510040}.
FT                                /FTId=VAR_060943.
FT   VARIANT     471    471       S -> N (in NBIA1; dbSNP:rs137852963).
FT                                {ECO:0000269|PubMed:11479594}.
FT                                /FTId=VAR_015165.
FT   VARIANT     489    489       L -> P (in NBIA1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:27185474}.
FT                                /FTId=VAR_076596.
FT   VARIANT     497    497       I -> T (in NBIA1).
FT                                {ECO:0000269|PubMed:11479594}.
FT                                /FTId=VAR_015166.
FT   VARIANT     500    500       N -> I (in NBIA1; dbSNP:rs759332123).
FT                                {ECO:0000269|PubMed:11479594}.
FT                                /FTId=VAR_015167.
FT   VARIANT     501    501       I -> T (in NBIA1; atypical;
FT                                dbSNP:rs775459398).
FT                                {ECO:0000269|PubMed:12510040}.
FT                                /FTId=VAR_060944.
FT   VARIANT     509    509       A -> V (in NBIA1).
FT                                {ECO:0000269|PubMed:12510040}.
FT                                /FTId=VAR_060945.
FT   VARIANT     511    511       N -> D (in NBIA1; dbSNP:rs767653843).
FT                                {ECO:0000269|PubMed:12510040}.
FT                                /FTId=VAR_060946.
FT   VARIANT     521    521       G -> R (in NBIA1; classic and atypical
FT                                forms; dbSNP:rs137852959).
FT                                {ECO:0000269|PubMed:11479594,
FT                                ECO:0000269|PubMed:15834858,
FT                                ECO:0000269|PubMed:24075960}.
FT                                /FTId=VAR_015168.
FT   VARIANT     528    528       T -> M (in NBIA1; classic and atypical
FT                                forms; unknown pathological significance;
FT                                dbSNP:rs137852967).
FT                                {ECO:0000269|PubMed:11479594,
FT                                ECO:0000269|PubMed:27185474}.
FT                                /FTId=VAR_015169.
FT   VARIANT     532    532       R -> W (in NBIA1).
FT                                {ECO:0000269|PubMed:12510040}.
FT                                /FTId=VAR_060947.
FT   VARIANT     555    555       G -> S (in NBIA1; atypical; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:24075960}.
FT                                /FTId=VAR_076597.
FT   VARIANT     563    563       L -> P (in NBIA1).
FT                                {ECO:0000269|PubMed:12510040}.
FT                                /FTId=VAR_060948.
FT   VARIANT     570    570       P -> L (in NBIA1; atypical;
FT                                dbSNP:rs41279408).
FT                                {ECO:0000269|PubMed:12510040,
FT                                ECO:0000269|PubMed:15834858}.
FT                                /FTId=VAR_060949.
FT   CONFLICT    460    460       R -> G (in Ref. 2; BAB13897).
FT                                {ECO:0000305}.
FT   CONFLICT    475    475       M -> K (in Ref. 2; BAB13897).
FT                                {ECO:0000305}.
FT   STRAND      213    218       {ECO:0000244|PDB:5E26}.
FT   STRAND      220    231       {ECO:0000244|PDB:5E26}.
FT   HELIX       235    240       {ECO:0000244|PDB:5E26}.
FT   HELIX       243    254       {ECO:0000244|PDB:5E26}.
FT   STRAND      256    258       {ECO:0000244|PDB:5E26}.
FT   TURN        259    261       {ECO:0000244|PDB:5E26}.
FT   STRAND      262    264       {ECO:0000244|PDB:5E26}.
FT   HELIX       266    268       {ECO:0000244|PDB:5E26}.
FT   STRAND      270    275       {ECO:0000244|PDB:5E26}.
FT   STRAND      278    288       {ECO:0000244|PDB:5E26}.
FT   HELIX       289    291       {ECO:0000244|PDB:5E26}.
FT   HELIX       292    301       {ECO:0000244|PDB:5E26}.
FT   HELIX       304    306       {ECO:0000244|PDB:5E26}.
FT   STRAND      309    315       {ECO:0000244|PDB:5E26}.
FT   HELIX       317    320       {ECO:0000244|PDB:5E26}.
FT   HELIX       322    329       {ECO:0000244|PDB:5E26}.
FT   STRAND      332    336       {ECO:0000244|PDB:5E26}.
FT   HELIX       338    352       {ECO:0000244|PDB:5E26}.
FT   STRAND      354    357       {ECO:0000244|PDB:5E26}.
FT   STRAND      359    365       {ECO:0000244|PDB:5E26}.
FT   TURN        369    371       {ECO:0000244|PDB:5E26}.
FT   STRAND      373    377       {ECO:0000244|PDB:5E26}.
FT   STRAND      384    403       {ECO:0000244|PDB:5E26}.
FT   STRAND      405    412       {ECO:0000244|PDB:5E26}.
FT   HELIX       415    426       {ECO:0000244|PDB:5E26}.
FT   HELIX       431    439       {ECO:0000244|PDB:5E26}.
FT   HELIX       443    445       {ECO:0000244|PDB:5E26}.
FT   STRAND      447    449       {ECO:0000244|PDB:5E26}.
FT   HELIX       450    454       {ECO:0000244|PDB:5E26}.
FT   HELIX       459    461       {ECO:0000244|PDB:5E26}.
FT   STRAND      467    470       {ECO:0000244|PDB:5E26}.
FT   TURN        471    476       {ECO:0000244|PDB:5E26}.
FT   HELIX       478    483       {ECO:0000244|PDB:5E26}.
FT   HELIX       486    512       {ECO:0000244|PDB:5E26}.
FT   STRAND      516    521       {ECO:0000244|PDB:5E26}.
FT   HELIX       522    524       {ECO:0000244|PDB:5E26}.
FT   HELIX       528    541       {ECO:0000244|PDB:5E26}.
FT   TURN        542    544       {ECO:0000244|PDB:5E26}.
FT   STRAND      547    553       {ECO:0000244|PDB:5E26}.
FT   HELIX       557    566       {ECO:0000244|PDB:5E26}.
SQ   SEQUENCE   570 AA;  62681 MW;  9061A60D6CA93BBB CRC64;
     MRRLGPFHPR VHWAAPPSLS SGLHRLLFLR GTRIPSSTTL SPPRHDSLSL DGGTVNPPRV
     REPTGREAFG PSPASSDWLP ARWRNGRGGR PRARLCSGWT AAEEARRNPT LGGLLGRQRL
     LLRMGGGRLG APMERHGRAS ATSVSSAGEQ AAGDPEGRRQ EPLRRRASSA SVPAVGASAE
     GTRRDRLGSY SGPTSVSRQR VESLRKKRPL FPWFGLDIGG TLVKLVYFEP KDITAEEEEE
     EVESLKSIRK YLTSNVAYGS TGIRDVHLEL KDLTLCGRKG NLHFIRFPTH DMPAFIQMGR
     DKNFSSLHTV FCATGGGAYK FEQDFLTIGD LQLCKLDELD CLIKGILYID SVGFNGRSQC
     YYFENPADSE KCQKLPFDLK NPYPLLLVNI GSGVSILAVY SKDNYKRVTG TSLGGGTFFG
     LCCLLTGCTT FEEALEMASR GDSTKVDKLV RDIYGGDYER FGLPGWAVAS SFGNMMSKEK
     REAVSKEDLA RATLITITNN IGSIARMCAL NENINQVVFV GNFLRINTIA MRLLAYALDY
     WSKGQLKALF SEHEGYFGAV GALLELLKIP
//
